CNTN1 and myeloid sarcoma: Axonal damage that underlies disease progression in MS could cause increased release of CNTN1 in body fluids during the active phase, whereas decreased CNTN1 levels could reflect the reduced axonal density that is found in progressive MS patients32,33 or reflect reduced CNTN1 RNA transcription.